Skip to main content
. Author manuscript; available in PMC: 2019 Sep 1.
Published in final edited form as: Thromb Haemost. 2018 Aug 13;118(9):1637–1645. doi: 10.1055/s-0038-1668521

Table 2.

Associations between oral anticoagulation and mortality. Odds ratios (ORs) and 95% confidence intervals (CIs) for 3 and 6 month all-cause mortality comparing the use of oral anticoagulants for the treatment of venous thromboembolism, OptumLabs Data Warehouse, 2012–2017.

N N all-cause deaths OR (95% CI) for all-cause mortality
3 months 6 months
3 months 6 months Crude IPTW MSM Crude IPTW MSM
DOAC vs warfarin comparisons
 Warfarin 35,704 802 1,208 -- -- -- --
 Rivaroxaban 21,064 299 428 0.63 (0.55, 0.72) 0.98 (0.83, 1.16) 0.59 (0.53, 0.66) 0.97 (0.84, 1.11)
 Warfarin 16,269 364 545 -- -- -- --
 
 Apixaban 5,663 112 155 0.88 (0.71, 1.09) 0.96 (0.74, 1.26) 0.81 (0.68, 0.97) 0.91 (0.72, 1.15)

DOAC vs DOAC comparisons
 Rivaroxaban 14,630 202 278 -- -- -- --
 Apixaban 5,663 112 155 1.44 (1.14, 1.82) 1.05 (0.81, 1.37) 1.45 (1.19, 1.77) 1.07 (0.86, 1.34)

DOAC: direct oral anticoagulant; IPTW MSM: inverse probability of treatment weighted marginal structural model IPTW weights were estimated using a logistic regression model for treatment, including the covariates age, age2, sex, census region, index date, index date2, diagnosis setting, the constituent Charlson and Elixhauser comorbidity and frailty variables, and concomitant medications.